Boston, MA -- (SBWIRE) -- 03/16/2016 -- Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Get More Details on this Report and a Full Table of Contents at Global Myocardial Infarction Drugs Market 2016-2020

Technavio's analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-AstraZeneca
-Bayer HealthCare
-Eli Lilly
-Novartis
-Pfizer
-Sanofi

Other prominent vendors

-advanceCOR
-Armaron Bio
-Athersys
-BioVascular
-BMS
-Caladrius
-Capricor
-CSL Behring
-GNT Pharma
-GSK
-Ischemix
-Mesoblast
-NeuroVive
-Osiris Therapeutics
-PledPharma
-RegeneRx
-Teva Pharmaceuticals
-TiGenix
-US Stem Cell
-Ventrix

Market driver

-Growing older population
-For a full, detailed list, view our report

Market challenge

-Alternative therapies
-For a full, detailed list, view our report

Market trend

-Growing awareness of disease
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, Sanofi, advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, Ventrix

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Myocardial Infarction Global Clinical Trials Review, H2, 2015
-Post-Myocardial Infarction Global Clinical Trials Review, H2, 2015
-Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H2, 2015
-Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019
-Myocardial Infarction - Pipeline Review, H2 2015